Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe?
The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players such as ACT-101 (Alpha Cancer Technologies). The drugs with substantial evidence hold immense promise for revolutionizing the treatment of autoimmune diseases. Let's delve into the current competitive landscape, exploring both approved and emerging players. Currently, FcRn inhibitors are approved in three indications including Myasthenia gravis, primary...
